Phenotypes associated with this allele

• Allele Symbol: Map3k7^tm1.1Gkl
• Allele Name: targeted mutation 1.1, George Kollias
• Allele ID: MGI:5576979
• Summary: 1 genotype

Jump to	Allelic Composition	Genetic Background	Genotype ID
cn1	Map3k7^tm1.1Gkl/Map3k7^tm1.1Gkl Lyz2^tm1(cre)Ifo/Lyz2^+	involves: 129P2/OlaHsd * C57BL/6	MGI:5577060

Genotype
MGI:5577060

cn1

• Allelic Composition: Map3k7^tm1.1Gkl/Map3k7^tm1.1Gkl; Lyz2^tm1(cre)Ifo/Lyz2⁺
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

mortality/aging

increased susceptibility to induced morbidity/mortality ( J:211916 )

• in LPS-treated mice

immune system

increased circulating interleukin-1 beta level ( J:211916 )

• 2-fold higher 3 hours after LPS treatment

decreased circulating interleukin-10 level ( J:211916 )

• in LPS-treated mice

increased circulating tumor necrosis factor level ( J:211916 )

• 1.5-fold 1.5 hours after LPS treatment

increased interleukin-1 beta secretion ( J:211916 )

• from bone marrow-derived macrophages stimulated with LPS at 3 and 12 hours

• from thioglycollate-elicited peritoneal neutrophils stimulated with LPS at 0, 6 and 12 hours

decreased interleukin-10 secretion ( J:211916 )

• from bone marrow-derived macrophages stimulated with LPS

increased interleukin-10 secretion ( J:211916 )

• from thioglycollate-elicited peritoneal neutrophils stimulated with LPS at 6 hours

increased interleukin-6 secretion ( J:211916 )

• from bone marrow-derived macrophages stimulated with LPS at 3 and 6 hours

• from thioglycollate-elicited peritoneal neutrophils stimulated with LPS at 0, 6 and 12 hours

increased tumor necrosis factor secretion ( J:211916 )

• from bone marrow-derived macrophages stimulated with LPS only at 3 hours

• from thioglycollate-elicited peritoneal neutrophils stimulated with LPS at 0, 6 and 12 hours

increased inflammatory response ( J:211916 )

• hyperinflammatory phenotype in bone marrow-derived macrophages stimulated with LPS

increased susceptibility to endotoxin shock ( J:211916 )

• LPS-treated mice exhibit increase mortality to endotoxemia and cytokine production compared with control mice

homeostasis/metabolism

increased circulating interleukin-1 beta level ( J:211916 )

• 2-fold higher 3 hours after LPS treatment

decreased circulating interleukin-10 level ( J:211916 )

• in LPS-treated mice

increased circulating tumor necrosis factor level ( J:211916 )

• 1.5-fold 1.5 hours after LPS treatment